[鸟氨酸转氨甲酰酶缺乏症的基因治疗] - Suppr

Suppr

超能文献

[Gene therapy for ornithine transcarbamylase deficiency].

作者信息

Matsuda I, Kiwaki K, Komaki S, Hoshide R, Matsuura T, Endo F

机构信息

Department of Pediatrics, Kumamoto University School of Medicine, Japan.

出版信息

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2759-64.

PMID:8584733

Abstract

摘要

相似文献

[Gene therapy for ornithine transcarbamylase deficiency].

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2759-64.

[Gene therapy for ornithine transcarbamylase (OTC) deficient mice].

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2674-8.

Mol Ther. 2006 Jul;14(1):1-2. doi: 10.1016/j.ymthe.2006.05.011. Epub 2006 Jun 5.

Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.

J Clin Invest. 1996 Feb 1;97(3):826-32. doi: 10.1172/JCI118482.

Gene therapy on trial.

Science. 2000 May 12;288(5468):951-7.

Virus treatment questioned after gene therapy death.

Nature. 1999 Oct 7;401(6753):517-8. doi: 10.1038/43977.

Gene therapy for ornithine transcarbamylase deficiency.

Acta Paediatr Jpn. 1996 Apr;38(2):189-92. doi: 10.1111/j.1442-200x.1996.tb03467.x.

Gene therapy for human liver disease.

Prog Liver Dis. 1995;13:201-30.

Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.

Hum Gene Ther. 1996 May 1;7(7):821-30. doi: 10.1089/hum.1996.7.7-821.

In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.

Gene Ther. 2009 Jun;16(6):820-3. doi: 10.1038/gt.2009.38. Epub 2009 Apr 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Gene therapy for ornithine transcarbamylase deficiency].

作者信息

Matsuda I, Kiwaki K, Komaki S, Hoshide R, Matsuura T, Endo F

机构信息

Department of Pediatrics, Kumamoto University School of Medicine, Japan.

出版信息

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2759-64.

PMID:8584733

Abstract

摘要

相似文献

[Gene therapy for ornithine transcarbamylase deficiency].

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2759-64.

[Gene therapy for ornithine transcarbamylase (OTC) deficient mice].

Tanpakushitsu Kakusan Koso. 1995 Dec;40(17):2674-8.

Mol Ther. 2006 Jul;14(1):1-2. doi: 10.1016/j.ymthe.2006.05.011. Epub 2006 Jun 5.

Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.

J Clin Invest. 1996 Feb 1;97(3):826-32. doi: 10.1172/JCI118482.

Gene therapy on trial.

Science. 2000 May 12;288(5468):951-7.

Virus treatment questioned after gene therapy death.

Nature. 1999 Oct 7;401(6753):517-8. doi: 10.1038/43977.

Gene therapy for ornithine transcarbamylase deficiency.

Acta Paediatr Jpn. 1996 Apr;38(2):189-92. doi: 10.1111/j.1442-200x.1996.tb03467.x.

Gene therapy for human liver disease.

Prog Liver Dis. 1995;13:201-30.

Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.

Hum Gene Ther. 1996 May 1;7(7):821-30. doi: 10.1089/hum.1996.7.7-821.

In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.

Gene Ther. 2009 Jun;16(6):820-3. doi: 10.1038/gt.2009.38. Epub 2009 Apr 9.